Recent News

• 09.12.2025 - InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 07.11.2025 - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
• 05.28.2025 - InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
• 05.22.2025 - InflaRx to Participate in Upcoming Investor Conferences

Recent Filings

• 08.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.07.2025 - EX-99.1 EX-99.1
• 07.14.2025 - EX-99.1 EX-99.1
• 07.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.11.2025 - UPLOAD SEC-generated letter
• 06.03.2025 - CORRESP Correspondence
• 05.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.28.2025 - EX-99.1 EX-99.1
• 05.22.2025 - UPLOAD SEC-generated letter